Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regrets For Valeant's Ackman, Pearson; Big Pay For Papa

Executive Summary

Outgoing Valeant Pharmaceuticals International Inc.'s CEO Michael Pearson and board member Bill Ackman expressed regret during an April 27 Senate hearing about the price hikes of some of the Canadian firm's drugs and pledged change at the embattled company. Meanwhile, the company in a late-day securities filing disclosed it planned to pay incoming CEO Joseph Papa more than $67m in cash, restricted stock and options, which shocked and angered the Senate committee leaders.


Related Content

Ackman 'Throws In The Towel' – What's Next For Valeant?
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Amgen's Harper Says Repatha Is Priced Right
Valeant: Seeking Disaster Expert To Run A Hot Mess
Beware The 'Pitchforks,' Pharma
Valeant: Another Fine Mess
It Was Shkreli's Show, But Pharma Was On Trial
Generics 'Express Lane' Urged To Rival High-Priced Drugs
Valeant CEO Hospitalization, Medical Leave Vexes Investors
Americans 'Hostages' To 'Ransom' Drug Prices, Senators Charge





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts